-
Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery diseaseYiY Zheng, TT Wu, X Xie et al. -
Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin?KM Ziada; DJ Moliterno et al.
-
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialHahn JY, Song YB, SMART-DATE investigators et al.
-
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelorM Verdoiaab, M Nardinb, R Gioscia et al.
-
Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical TrialR Mehran, J Chandrasekhar, P Urban et al.
-
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS studyChen Y, Yin T, Xi S et al.
-
Polymer-based or Polymer-free Stents in Patients at High Bleeding RiskS Windecker, A Latib, the ONYX ONE Investigators et al.
-
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registrySahlén A, Varenhorst C, Lagerqvist B et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
